Skip to main content
Janakiraman Subramanian, MD, Oncology, Fairfax, VA

JanakiramanSubramanianMDMPH

Oncology Fairfax, VA

Hematologic Oncology, Thoracic Cancer

Co Director Thoracic Oncology

Dr. Subramanian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Subramanian's full profile

Already have an account?

  • Office

    8081 Innovation Park Dr
    Level 4 - White Oak Clinic
    Fairfax, VA 22031
    Phone+1 571-472-1380
    Fax+1 571-472-1294

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2010
  • St Luke's Hospital
    St Luke's HospitalResidency, Internal Medicine, 2003 - 2006
  • Sri Ramachandra Medical College
    Sri Ramachandra Medical CollegeClass of 2000

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2021 - 2026
  • KS State Medical License
    KS State Medical License 2015 - 2025
  • MO State Medical License
    MO State Medical License 2006 - 2025
  • TN State Medical License
    TN State Medical License 2012 - 2018
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • The Role of Chemotherapy in the Treatment of Stage II Nasopharyngeal Carcinoma: Retrospective Analysis of the National Cancer Database
    The Role of Chemotherapy in the Treatment of Stage II Nasopharyngeal Carcinoma: Retrospective Analysis of the National Cancer DatabaseFebruary 21st, 2020
  • Genomic Testing Solves Cancer Misdiagnosis
    Genomic Testing Solves Cancer MisdiagnosisMarch 14th, 2019
  • Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
    Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient CohortAugust 8th, 2024

Professional Memberships

Other Languages

  • Tamil